Kinnate Biopharma Other Current Assets

As of the most recent data (December 2023), KNTE shows a other current assets of $4.1M. That compares with $3.6M in the prior-year period — up 13.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, KNTE's other current assets is now $4.1M (was $3.6M) — a 13.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Kinnate Biopharma is outperforming or lagging.

Tracking KNTE's other current assets over time shows whether Kinnate Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $4.1M That compares with $3.6M in the prior-year period — up 13.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has Kinnate Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $4.1M) with ownership activity and broader fundamentals.

Kinnate Biopharma's other current assets is $4.1M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.